Biocartis Group NV: Biocartis launches innovative

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
68
Biocartis Group NV: Biocartis launches innovative Idylla(TM) MSI Assay

 

PRESS RELEASE: 17 July 2018, 07:00 CEST


Biocartis launches innovative Idylla(TM) MSI Assay

Idylla(TM) MSI Assay further strengthens Biocartis' test menu and offers opportunities to enter the immuno-oncology testing market

Mechelen, Belgium, 17 July 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the launch of its innovative and fully automated Idylla(TM) MSI[1] Assay (RUO[2]). The Idylla(TM) MSI Assay provides information on the MSI status[3],[4],[5] (i.e. MSI-High or Microsatellite stable) of a tumor within approximately 150 minutes from just one slice of FFPE[6]tumor tissue, without requiring a reference sample.

MSI is the result of inactivation of the body's so-called DNA mismatch repair (MMR) system. Consequently, errors that normally spontaneously occur during DNA replication are no longer corrected, contributing to tumor growth and evolution. Current MSI testing methods rely on manual, lengthy and complex procedures involving amongst others obtaining and testing of a second reference sample.

The fully automated Idylla(TM) MSI Assay includes a novel set of seven MSI biomarkers, consisting of short homopolymers located in the ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A and SULF2 genes. These were exclusively licensed to Biocartis in 2013 from VIB, the life sciences research institute in Flanders (Belgium), and originated from the research of the group of Prof. Diether Lambrechts (VIB-KU Leuven, Belgium).

Several multi-center studies2,3,4 comparing the standard methods[7] with the Idylla(TM) MSI Assay showed a >95% concordance between results. Furthermore, compared to standard methods,the Idylla(TM) MSI Assay has a significantly lower failure rate2,3,4,provides automated result reporting and includes MSI-specific pan-tumor biomarkers, independent of ethnicity2,3,4.

Herman Verrelst, Chief Executive Officer of Biocartis, commented: "Our fully automated Idylla(TM) MSI Assay, once validated for diagnostic use, will significantly strengthen our colorectal cancer test menu. This test is expected to overcome the drawbacks of conventional MSI testing, and could as such be made available to a much larger patient population. While the test is planned to initially be launched for colorectal cancer, MSI is present in several other tumor types as well, such as gastric and endometrial cancer, providing additional opportunities going forward. Finally, since MSI is an independent factor that may predict a patient's response to certain immunotherapies[8], we can now further explore opportunities to enter into the field of immuno-oncology[9] as the importance of MSI testing in that market is growing."

Dr. Alexander Mackinnon, Director - Clinical and Translational Research Core Lab at the Medical College of Wisconsin (US), reacted: "Current MSI testing methods are often laborious and difficult to optimize.  Furthermore, conventional MSI testing requires both normal and malignant tumor tissue. The Idylla(TM) MSI test is a simple, fully automated solution requiring only tumor tissue for the determination of MSI status. It provides rapid results that are highly concordant with conventional testing methods".

The CE-marking of the Idylla(TM) MSI Assay for in vitro diagnostic use in colorectal cancer is anticipated in 2019.

 --- END ---

 

 More information:

Renate Degrave

Manager Corporate Communications & Investor Relations

e-mail    rdegrave@biocartis.com

tel         +32 15 631 729
mobile   +32 471 53 60 64

About Biocartis 

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers fifteen oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

Biocartis and Idylla(TM) are registered trademarks in Europe, the United States and other countries. Biocartis trademark and logo and Idylla(TM) trademark and logo are used trademarks belonging to Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements.

 



[1] MSI = microsatellite instability.

[2] Research Use Only, not for use in diagnostic procedures.

[3] Maertens G. et al. Annals of Oncology (2017) 28 (suppl_5): v22-v42.

[4] De Craene B. et al. Annals of Oncology (2017) 28 (suppl_5): v209-v268.

[5] De Craene et al. J Clin Oncol 36, 2018 (suppl; abstr e15639)>.

[6] FFPE = formalin fixed, paraffin embedded.

[7] Including IHC and Promega MSI analysis system 1.2.

[8] In a recent study in collaboration with Prof. Diether Lambrechts (VIB-KU Leuven, Belgium) presented at ASCO, the number of Idylla(TM) MSI Biomarkers were shown to be associated with total indel load and tumor mutational burden in endometrial tumors and in colorectal cancer (source: Zhao et al. J Clin Oncol 36, 2018 (suppl; abstr e15654).

[9] Recent data have shown that advanced colorectal cancer patients with an MSI-high status respond particularly well to certain immunotherapies (Xiao Y et al. (2015) The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 5, 16-18; and, Le et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372, 2509-2520). MSI status is also used to screen for patients with potential hereditary colorectal cancer (the so-called 'Lynch syndrome') and can help to guide later genetic testing of the patient and relatives.


Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 105

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 65

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
TSA at 25: Security Mission Meets a Tough Travel Reality

Updated Category News Views 104

Twenty-five years after its birth from catastrophe, TSA is still carrying a job nobody should take lightly. The agency marked its anniversary on November 19, 2026, looking back to the September 11, 2001 attacks that led to federalized aviation screening and a permanent reshaping of how Americans move through airports. This is not the sort of milestone that deserves...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 44

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 97

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 109

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 102

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 146

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Pickleman’s Chips Turn a Side Into a Brand Signal Now

Updated Category News Views 79

A bag of dill pickle chips is hardly earthshaking news, yet this one says plenty about where fast-casual brands are trying to compete. Pickleman’s Gourmet Cafe is launching its own proprietary chip line with non-GMO ingredients, sunflower oil, a pared-down ingredient profile, and a flavor that actually fits the name on the door. More importantly, a portion of each...

Continue Reading

Top 5 Most Recently Viewed Articles

FRNT Financial Expands Its Investment Portfolio with BTC

Updated Category News Views 101

FRNT Financial's New Bitcoin Acquisition FRNT Financial Inc. has made headlines with the recent purchase of 3.14 BTC (Bitcoin), which totals an impressive C$500,000, roughly equivalent to US$115,594 per BTC. This acquisition highlights the company’s robust strategy to widen its investment horizons by venturing into digital assets, showcasing their keen understanding of...

Continue Reading
Pasinex Reports Q2 2025 Results with Key Developments Ahead

Updated Category News Views 143

Pasinex Resources Limited Financial Highlights Pasinex Resources Limited (CSE: PSE) has released its financial results for the second quarter ended June 30, 2025. The company’s latest earnings report highlights both challenges and strategic advancements as it aims for growth in the zinc market. Quarterly Performance Overview In Q2 2025, Pasinex reported a net loss of...

Continue Reading
Join the Class Action Against Perpetua Resources Corp. Today

Updated Category News Views 201

Understanding the Class Action Against Perpetua Resources Corp. In recent developments, a significant class action lawsuit has been initiated on behalf of investors in Perpetua Resources Corp. (NASDAQ: PPTA). This lawsuit arises from allegations that the company misrepresented critical information regarding the Stibnite Gold Project, leading to substantial financial...

Continue Reading
Celebrating Excellence: 2026 ACGME International Award Recipients

Updated Category News Views 304

Celebrating the 2026 ACGME International Awards In a significant announcement that highlights dedication to global medical education, ACGME International (ACGME-I) celebrates the recipients of the 2026 ACGME International Awards. These awards recognize exceptional individuals within institutions accredited by ACGME-I, shining a light on their commitment to enhancing...

Continue Reading
APTIM Achieves Top 10 Ranking in Environmental Management Again

Updated Category News Views 79

APTIM Maintains Stellar Position in Environmental Rankings In an impressive feat for the fourth consecutive year, APTIM has been celebrated in the Top 10 Environmental Management Firms according to a prestigious ranking by Engineering News-Record (ENR). This year, APTIM proudly holds the seventh position in environmental management and tenth in the nuclear waste category....

Continue Reading